BillionToOne, Inc. BLLN
112.00 USD -2.95 (-2.57%)
At closeNov 10, 2026, 4:26 PM EST
112.00 0.00 0.00%
After hours · Nov 10, 4:26 PM ET
106.36 Day range 113.36
61.96 52-week range 150.44
- YTD
- +36.85%
- 1 year
- +9.57%
News
benzinga.com Piper Sandler Maintains Overweight on BillionToOne, Lowers Price Target to $130 Piper Sandler analyst David Westenberg maintains BillionToOne (NASDAQ:BLLN) with a Overweight and lowers the price target from $140 to $130.
defenseworld.net Insider Selling: Billiontoone (NASDAQ:BLLN) CTO Sells $2,184,800.00 in Stock Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) CTO David Tsao sold 20,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $109.24,…
benzinga.com JP Morgan Maintains Overweight on BillionToOne, Raises Price Target to $135 JP Morgan analyst Casey Woodring maintains BillionToOne (NASDAQ:BLLN) with a Overweight and raises the price target from $130 to $135.
seekingalpha.com BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
zacks.com BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
zacks.com BillionToOne (BLLN) Surpasses Q3 Earnings and Revenue Estimates BillionToOne (BLLN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.
marketbeat.com Billiontoone Q3 Earnings Call Highlights Billiontoone NASDAQ: BLLN raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular…
benzinga.com BillionToOne Q3 2026 Earnings Call Transcript BillionToOne (NASDAQ:BLLN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com BillionToOne Q4 EPS $0.32 Beats $0.28 Estimate, Sales $122.981M Beat $120.146M Estimate BillionToOne (NASDAQ:BLLN) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.28 by 14.29 percent. This is a 190.91 percent increase over earnings of $0.11…
benzinga.com BillionToOne Q3 EPS $0.32 Beats $0.19 Estimate, Sales $122.981M Beat $109.365M Estimate BillionToOne (NASDAQ:BLLN) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.19 by 68.42 percent. This is a 220 percent increase over earnings of $0.10…- benzinga.com BillionToOne Sees FY2027 Sales $460.000M-$470.000M vs $573.800M Est BillionToOne (NASDAQ:BLLN) sees FY2027 sales of $460.000 million-$470.000 million vs $573.800 million analyst estimate.
globenewswire.com BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are…- benzinga.com Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128 Guggenheim analyst Subbu Nambi maintains BillionToOne (NASDAQ:BLLN) with a Buy and raises the price target from $125 to $128.
benzinga.com Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
benzinga.com Canaccord Genuity Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $120 Canaccord Genuity analyst Kyle Mikson initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating and announces Price Target of $120.
benzinga.com Jim Cramer: 'You Could Make Some Money With This 5.6% Yield' Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
benzinga.com BillionToOne Publishes NIPT Study Titled A Prospective, Multi-Site Study Of Performance Of Cell-Free DNA Testing For Recessive Conditions In A Large, General-Risk Pregnancy Population BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com BTIG Maintains Buy on BillionToOne, Lowers Price Target to $130 BTIG analyst Mark Massaro maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price target from $142 to $130.
benzinga.com BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move BillionToOne stock fell after hours after reporting second-quarter financial results.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
benzinga.com BillionToOne Affirms FY2026 Sales Guidance of $450.000M-$465.000M vs $456.440M Est BillionToOne (NASDAQ:BLLN) affirms FY2026 sales outlook from $450.000 million-$465.000 million to $450.000 million-$465.000 million vs $456.440 million estimate.- benzinga.com BillionToOne Q3 EPS $0.15 Misses $0.19 Estimate, Sales $109.400M Beat $109.365M Estimate BillionToOne (NASDAQ:BLLN) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.19 by 21.05 percent. This is a 50 percent increase over earnings of $0.10…
benzinga.com Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Joby Aviation Is 'Too Risky,' But This Industrial Stock Is A 'Winner': Jim Cramer Cramer shared his thoughts on various stocks, calling Joby Aviation too risky, BillionToOne a winner, Boston Scientific caught in competition, Rocket Lab a winner, and Pinnacle West Capital a good…
benzinga.com Marriott Vacations To Rally Around 52%? Here Are 10 Top Analyst Forecasts For Thursday Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all changes. VEEV, GENI, DOW, BLLN, OKTA, VAC, WLK, EYPT had price target changes.- benzinga.com Earnings Scheduled For March 4, 2026
- benzinga.com Earnings Scheduled For December 9, 2025
benzinga.com ServiceTitan Posts Upbeat Q3 Results, Joins DigitalBridge, Rubrik, Victoria's Secret And Other Big Stocks Moving Higher On Friday 
benzinga.com This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday